PL1841433T3 - Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego - Google Patents

Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego

Info

Publication number
PL1841433T3
PL1841433T3 PL06712847T PL06712847T PL1841433T3 PL 1841433 T3 PL1841433 T3 PL 1841433T3 PL 06712847 T PL06712847 T PL 06712847T PL 06712847 T PL06712847 T PL 06712847T PL 1841433 T3 PL1841433 T3 PL 1841433T3
Authority
PL
Poland
Prior art keywords
composition
nervous system
central nervous
system disorders
treating central
Prior art date
Application number
PL06712847T
Other languages
English (en)
Polish (pl)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of PL1841433T3 publication Critical patent/PL1841433T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL06712847T 2005-01-27 2006-01-26 Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego PL1841433T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64700805P 2005-01-27 2005-01-27
EP06712847A EP1841433B1 (en) 2005-01-27 2006-01-26 Composition for treating central nervous system disorders
PCT/JP2006/301704 WO2006080549A2 (en) 2005-01-27 2006-01-26 Method and composition for treating central nervous system disorders

Publications (1)

Publication Number Publication Date
PL1841433T3 true PL1841433T3 (pl) 2012-07-31

Family

ID=36740907

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06712847T PL1841433T3 (pl) 2005-01-27 2006-01-26 Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego

Country Status (19)

Country Link
US (2) US8202909B2 (enExample)
EP (2) EP2332545A1 (enExample)
JP (1) JP5147404B2 (enExample)
KR (1) KR101354771B1 (enExample)
CN (1) CN101146541B (enExample)
AR (1) AR055846A1 (enExample)
AU (1) AU2006209072B2 (enExample)
BR (1) BRPI0607084A2 (enExample)
CA (1) CA2595898C (enExample)
DK (1) DK1841433T3 (enExample)
ES (1) ES2375082T3 (enExample)
IL (1) IL184578A (enExample)
NO (1) NO340257B1 (enExample)
NZ (1) NZ556710A (enExample)
PL (1) PL1841433T3 (enExample)
PT (1) PT1841433E (enExample)
RU (1) RU2440338C2 (enExample)
TW (1) TWI384988B (enExample)
WO (1) WO2006080549A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
US20080207759A1 (en) * 2007-02-27 2008-08-28 Sucampo Ag Method for protecting mitochondria
JP5390519B2 (ja) * 2007-07-19 2014-01-15 株式会社アールテック・ウエノ １１−デオキシ−プロスタグランジン化合物を含む医薬組成物およびその安定化方法
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US9084815B2 (en) 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
EP2627647B1 (en) * 2010-10-15 2016-12-14 Scinopharm (Kunshan) Biochemical Technology Co., Ltd. Processes for preparation of lubiprostone
JP6023082B2 (ja) * 2011-01-24 2016-11-09 インセプタム リサーチ アンド セラピューティクス，インク． 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物
BR112013026644A2 (pt) * 2011-04-19 2016-12-27 Sucampo Ag método para a modulação da atividade de citocina
CN107903173A (zh) * 2011-08-05 2018-04-13 苏坎波公司 治疗精神分裂症的方法
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
MX364197B (es) * 2014-10-21 2019-04-16 Univ Illes Balears Proceso de sintesis de hidroxi-triacilgliceroles y usos de los mismos para la prevencion y el tratamiento de enfermedades.

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120243A (en) 1970-03-09 1968-07-17 Samuelsson Bengt Improvements in or relating to unsaturated carboxylic acid derivatives and the manufacture thereof
BE786215A (fr) 1971-07-14 1973-01-15 American Cyanamid Co Nouveaux composes apparentes aux prostaglandines naturelles et procedesde leur preparation
ZA764727B (en) * 1975-09-02 1977-07-27 Upjohn Co Prostanoic acid derivatives
SU845774A3 (ru) 1976-04-20 1981-07-07 Фармиталия Карло Эрба С.П.А. (Фирма) Способ получени 13,14-дегидро-11-дЕзОКСипРОСТАглАНдиНОВ
US4131738A (en) * 1977-07-05 1978-12-26 The Upjohn Company 6-Hydroxy-PGE1 compounds
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
DE69106744T2 (de) 1990-02-26 1995-05-18 Ueno Seiyaku Oyo Kenkyujo Kk 15-Dehydroxy-16-oxoprostaglandine.
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
JPH04187637A (ja) * 1990-11-21 1992-07-06 Ueno Seiyaku Oyo Kenkyusho:Kk 記憶改善剤
JPH07113012B2 (ja) 1991-01-29 1995-12-06 株式会社アールテック・ウエノ 新規１５−ケト−プロスタグランジン類
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
JP3187438B2 (ja) 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
CA2279267C (en) * 1997-11-28 2010-01-12 R-Tech Ueno, Ltd. Use of 15-ketoprostaglandin e compounds as endothelin antagonist
JP3703004B2 (ja) 1998-07-15 2005-10-05 小野薬品工業株式会社 ５−チア−ω−置換フェニル−プロスタグランジンＥ誘導体
WO2000051978A1 (en) * 1999-03-01 2000-09-08 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
TWI225398B (en) 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
NZ521464A (en) * 2000-03-24 2004-09-24 Sucampo Ag Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
CN1214794C (zh) * 2003-09-08 2005-08-17 秦正红 前列腺素a1在制备治疗脑缺血性中风疾病的药物中的用途

Also Published As

Publication number Publication date
US20120225938A1 (en) 2012-09-06
AU2006209072B2 (en) 2011-02-24
IL184578A (en) 2015-02-26
AR055846A1 (es) 2007-09-12
NZ556710A (en) 2010-08-27
KR101354771B1 (ko) 2014-01-22
EP1841433B1 (en) 2011-11-30
US8202909B2 (en) 2012-06-19
CN101146541B (zh) 2012-04-11
CN101146541A (zh) 2008-03-19
US20060194880A1 (en) 2006-08-31
JP5147404B2 (ja) 2013-02-20
WO2006080549A2 (en) 2006-08-03
ES2375082T3 (es) 2012-02-24
TW200642690A (en) 2006-12-16
CA2595898A1 (en) 2006-08-03
DK1841433T3 (da) 2012-01-16
RU2440338C2 (ru) 2012-01-20
HK1118716A1 (en) 2009-02-20
BRPI0607084A2 (pt) 2009-08-04
AU2006209072A1 (en) 2006-08-03
RU2007132081A (ru) 2009-03-10
NO20074332L (no) 2007-10-17
CA2595898C (en) 2015-04-28
IL184578A0 (en) 2007-10-31
NO340257B1 (no) 2017-03-27
JP2008528440A (ja) 2008-07-31
KR20070107065A (ko) 2007-11-06
WO2006080549A3 (en) 2007-07-05
TWI384988B (zh) 2013-02-11
EP2332545A1 (en) 2011-06-15
PT1841433E (pt) 2012-02-01
EP1841433A2 (en) 2007-10-10

Similar Documents

Publication Publication Date Title
IL186450A0 (en) Methods for treating anxiety related disorders
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL180187A (en) Composition for treating inflammatory disorders
IL185016A0 (en) Compounds for the treatment of proliferative disorders
IL190913B (en) Preparations for the treatment of sweating disorders
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
AP2006003771A0 (en) Substituted morpholine compounds for the treatmentof central nervous system disorders
ZA200809528B (en) Treatment for depressive disorders
IL183985A0 (en) Methods for treating autoimmune disorders
IL184456A0 (en) Dosage form for treating gastrointestinal disorders
IL184578A0 (en) Method and composition for treating central nervous system disorders
ZA200809527B (en) Treatment for depressive disorders
ZA200801401B (en) Carbamate compounds for use in treating neurodegenerative disorders
PL1993589T3 (pl) Sposoby leczenia chorób neurologicznych
ZA200610661B (en) Compositions and methods for treating neurological disorders
ZA200809284B (en) Polymorph forms of (2S) - (4E) -N-Methyl-5- )3-Isopropoxypyridin) YL]-4-Penten-2-amine for the treatment of central nervous system disorders
IL187439A0 (en) Compounds useful for treating neurodegenerative disorders
ZA200804951B (en) Compositions and methods for treating CNS disorders
IL198856A0 (en) Compounds useful for treating neurodegenerative disorders
EP1868434A4 (en) BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
IL162288A0 (en) Compositions and methods for treating neurodegenerative disorders
EP1859277A4 (en) TREATMENT OF NEUROLOGICAL DISORDERS
IL185911A0 (en) Dipyrazoles as central nervous system agents
IL176836A0 (en) Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
PT2481407T (pt) Compostos para utilização no tratamento de distúrbios cognitivos